Lectures on Spectrum Generating Symmetries and U-duality in Supergravity, Extremal Black Holes, Quantum Attractors and Harmonic Superspace

We review the underlying algebraic structures of supergravity theories with symmetric scalar manifolds in five and four dimensions, orbits of their extremal black hole solutions and the spectrum generating extensions of their U-duality groups. For 5D, N=2 Maxwell-Einstein supergravity theories (MESGT) defined by Euclidean Jordan algebras, J, the spectrum generating symmetry groups are the conformal groups Conf(J) of J which are isomorphic to their U-duality groups in four dimensions. Similarly, the spectrum generating symmetry groups of 4D, N=2 MESGTs are the quasiconformal groups QConf(J) associated with J that are isomorphic to their U-duality groups in three dimensions. We then review the work on spectrum generating symmetries of spherically symmetric stationary 4D BPS black holes, based on the equivalence of their attractor equations and the equations for geodesic motion of a fiducial particle on the target spaces of corresponding 3D supergravity theories obtained by timelike reduction. We also discuss the connection between harmonic superspace formulation of 4D, N=2 sigma models coupled to supergravity and the minimal unitary representations of their isometry groups obtained by quantizing their quasiconformal realizations. We discuss the relevance of this connection to spectrum generating symmetries and conclude with a brief summary of more recent results.Comment: 55 pages; Latex fil

Spectrum Generating Conformal and Quasiconformal U-Duality Groups, Supergravity and Spherical Vectors

After reviewing the algebraic structures that underlie the geometries of N=2 Maxwell-Einstein supergravity theories (MESGT) in five and four dimensions with symmetric scalar manifolds, we give a unified realization of their three dimensional U-duality groups as spectrum generating quasiconformal groups. They are F_{4(4)}, E_{6(2)}, E_{7(-5)}, E_{8(-24)} and SO(n+2,4). Our formulation is covariant with respect to U-duality symmetry groups of corresponding five dimensional supergravity theories, which are SL(3,R), SL(3,C), SU*(6), E_{6(6)} and SO(n-1,1)X SO(1,1), respectively. We determine the spherical vectors of quasiconformal realizations of all these groups twisted by a unitary character. We also give their quadratic Casimir operators and determine their values. Our work lays the algebraic groundwork for constructing the unitary representations of these groups induced by their geometric quasiconformal actions, which include the quaternionic discrete series. For rank 2 cases, SU(2,1) and G_{2(2)}, corresponding to simple N=2 supergravity in four and five dimensions, this program was carried out in arXiv:0707.1669. We also discuss the corresponding algebraic structures underlying symmetries of matter coupled N=4 and N>4 supergravity theories. They lead to quasiconformal realizations of split real forms of U-duality groups as a straightforward extension of the quaternionic real forms.Comment: Section 4 is split with the addition of a subsection on quadratic Casimir operators; references added; typos corrected. Latex file; 53 page

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie